Orexigen Therapeutics (OREX) Misses Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts OREX Hot Sheet
Price: $0.22 --0%
Financial Fact:
Loss from operations: 42.53M
Today's EPS Names:
TFS, PBNK, FNRN, More
Financial Fact:
Loss from operations: 42.53M
Today's EPS Names:
TFS, PBNK, FNRN, More
Join SI Premium – FREE
Orexigen Therapeutics (NASDAQ: OREX) reported Q4 EPS of ($0.12), $0.04 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $4.9 million versus the consensus estimate of $14.07 million.
According to IMS Health, 185,944 prescriptions of Contrave (naltrexone HCl and bupropion HCl extended-release tablets) were filled in the fourth quarter of 2015.
For earnings history and earnings-related data on Orexigen Therapeutics (OREX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TFS Financial (TFSL) Reports In-Line Q4 EPS
- KeyBanc Reiterates Sector Weight Rating on Starbucks (SBUX)
- Consensus Mining & Seigniorage Corporation (CMSG) Tops Q3 EPS by 331c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
